SARMNon-steroidalOralSARM

LGD-3303

Also known as LGD3303

Written by enwyReviewed 15 Jul 20261 sources0 comments

LGD-3303 is a non-steroidal SARM studied preclinically for muscle and bone, notably in osteoporosis models. It has no human data, so all information is preclinical or anecdotal. It shows good oral bioavailability in animals and is expected to share the class effects of testosterone suppression and lipid changes.

01 Overview

LGD-3303 was investigated by Ligand Pharmaceuticals in animal models of osteopenia, where it increased bone mineral density and muscle mass and worked additively with an antiresorptive agent. It has favourable oral properties in rodents.

No human trials have been conducted, so efficacy and safety in people are unknown. Recreationally it is used for lean-mass and strength goals with dosing extrapolated from anecdote. Like other SARMs it is expected to suppress endogenous testosterone and alter lipids, and it is unapproved and prohibited in sport.

02 Mechanism

Non-steroidal androgen-receptor agonist selective for anabolic activity in muscle and bone in animal models.

03 Dosing

Tier	Dose	Route	Notes
Light	10–15 mg/day	Oral	Anecdotal only; no validated human dose.
Common	15–30 mg/day	Oral	Higher anecdotal range; risks poorly characterised.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Increased bone mineral densityRodent osteopenia models showed increased bone density, additive with antiresorptive therapy.		Preclinical
Increased muscle massAnimal studies show anabolic effects on skeletal muscle.		Preclinical
Strength and size gainsUsers report gains; no human trials support this.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Lipid changes (HDL reduction)Reported HDL reductions, as with other SARMs.	Mild	Common	Anecdotal
Testosterone suppressionExpected suppression of endogenous testosterone consistent with androgen-receptor agonism; not quantified in humans.	Moderate	Common	Anecdotal
Unknown human safety profileNo human data exist to characterise safety.	Moderate	Unknown	Unconfirmed

06 Legal status

United Kingdom

Not licensed as a medicine

as of Jan 2026

United States

Not FDA-approved; unlawful as dietary supplement

as of Jan 2026

07 References

LGD-3303 preclinical effects on bone and musclePubMed

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.